Kenya Medical Research Institute (KEMRI)
Nairobi, Nairobi County, 00100, Kenya
NCT Number: NCT06213051
This study will compare the performance of self-collected vaginal swabs, transported without liquid media (dry swabs) and self-collected vaginal swabs, transported in liquid media (wet swabs) for detection of hrHPV DNA LBC as the reference standard.
Looking for future studies?
Notify Me30 year–80 year
Female
Observational
Nairobi, Nairobi County, 00100, Kenya
Self-collected vaginal samples for high-risk human papillomavirus (hrHPV) DNA testing are a promising alternative cervical cancer screening method for women who are reluctant to undergo healthcare provider-collection of cervical samples. Transportation of self-collected vaginal samples using swabs stored in liquid media incur additional costs and might create testing barriers for women. Dry transport of samples has the advantage of lower cost and ease of handling. Evidence on comparisons between self-collected vaginal samples using the dry swab and those transported in liquid media is limited, particularly in low- and middle-income countries (LMICs). The effect of using dry swabs on HPV-DNA detection in LMICs needs to be determined.
This study will compare the performance of self-collected vaginal swabs, transported without liquid media (dry swabs) and self-collected vaginal swabs, transported in liquid media (wet swabs) for detection of hrHPV DNA using LBC and as reference standard.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria for participants screened and enrolled consecutively as they present at the clinical study site:
Exclusion criteria
COPAN swabs evaluated on Roche COBAS and Cepheid Xpert PCRs
Other names: COPAN Self-collection FLOQSwabs® (COPAN, Italy) with 5ml PreservCyt Solution (Hologic)
Time frame: 6 Months
Relative sensitivity and specificity, along with the percentage difference (with 95% confidence intervals), to compare self-collected vaginal dry swabs to self-collected vaginal wet swabs for detection of hrHPV DNA using PCR as the reference standard.
Time frame: 6 Months
Relative sensitivity and specificity, along with the percentage difference (with 95% confidence intervals), to compare self-collected vaginal dry swabs to provider-collected cervical samples for detection of hrHPV to screen for CIN2+ lesions using LBC on health care provider-collected cervical samples as the reference standard.
Time frame: 6 Months
Relative sensitivity and specificity, along with the percentage difference (with 95% confidence intervals), to compare self-collected vaginal wet swabs to provider-collected cervical samples for detection of hrHPV to screen for CIN2+ lesions using LBC on health care provider-collected cervical samples as the reference standard.
Time frame: 6 Months
Relative sensitivity and specificity, along with the percentage difference (with 95% confidence intervals), to compare self-collected dry swabs to self-collected wet swabs for detection of hrHPV to screen for CIN2+ lesions using LBC on health care provider-collected cervical samples as the reference standard.
Time frame: 6 Months
Assessment of survey responses using descriptive statistics.
Time frame: 6 Months
Assessment of survey responses using descriptive statistics.
Looking for future studies?
Notify MeFoundation for Innovative New Diagnostics, Switzerland
Other
Clinical Study to Compare the Performance of Self-collected Vaginal Samples Transported Dry to Those Transported Wet for Detection of hrHPV DNA.
Acronym: HPV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07706673
Communicable Diseases, DNA Virus Infections
Liberia, Guanacaste Province, Costa Rica
View Trial DetailsNCT07833852
Cervical Intraepithelial Neoplasia, Communicable Diseases
Mianyang, Sichuan, China
View Trial DetailsNCT07820241
Communicable Diseases, DNA Virus Infections
Hezhou, Guangxi, China
View Trial DetailsNCT03036930
Communicable Diseases, DNA Virus Infections
Birmingham, Alabama, United States
View Trial Details